|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
109,470,000 |
Market
Cap: |
84.24(M) |
Last
Volume: |
627,989 |
Avg
Vol: |
626,283 |
52
Week Range: |
$0.5601 - $1.41 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Vaxart is a clinical-stage biotechnology company primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology proprietary oral vaccine platform. Co.'s oral vaccines are designed to generate immune responses that protect against a range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Co.'s investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. In addition, Co. is in early development of its first therapeutic vaccine targeting cervical cancer and dysplasia caused by human papillomavirus.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
25,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$31,240 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
2 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Aryeh Jason |
Director |
|
2010-10-18 |
4 |
S |
$5.00 |
$60,100 |
I/I |
(12,020) |
232,436 |
|
- |
|
Aryeh Jason |
Director |
|
2010-10-11 |
4 |
S |
$5.00 |
$22,110 |
I/I |
(4,422) |
244,456 |
|
- |
|
Kalnik Matthew W. |
SVP Strategic Plan. & Bus. Ops |
|
2010-07-26 |
4 |
AS |
$5.78 |
$8,670 |
D/D |
(1,500) |
44,225 |
|
- |
|
Kalnik Matthew W. |
SVP Strategic Plan. & Bus. Ops |
|
2010-07-19 |
4 |
AS |
$5.48 |
$8,905 |
D/D |
(1,625) |
45,725 |
|
- |
|
Aryeh Jason |
Director |
|
2010-06-11 |
4 |
S |
$5.74 |
$3,446 |
I/I |
(600) |
248,878 |
|
- |
|
Aryeh Jason |
Director |
|
2010-06-11 |
4 |
S |
$5.74 |
$12,324 |
I/I |
(2,147) |
249,478 |
|
- |
|
Aryeh Jason |
Director |
|
2010-06-03 |
4 |
S |
$5.81 |
$1,499 |
I/I |
(258) |
251,625 |
|
- |
|
Fahim Raafat E F |
President, CEO and CFO |
|
2010-05-31 |
4 |
A |
$4.20 |
$13,003 |
D/D |
3,096 |
333,734 |
|
- |
|
Davis Peter B |
Director |
|
2010-05-20 |
4 |
B |
$5.24 |
$19,996 |
D/D |
3,816 |
14,630 |
2.39 |
- |
|
Cox Geoffrey F |
Director |
|
2010-05-20 |
4 |
B |
$5.24 |
$9,998 |
D/D |
1,908 |
25,679 |
2.39 |
- |
|
Kessler Paul D. |
SVP Clinical, Med. & Reg.; CMO |
|
2010-05-17 |
4 |
AS |
$5.68 |
$85,685 |
D/D |
(15,000) |
98,252 |
|
- |
|
Kalnik Matthew W. |
SVP Strategic Plan. & Bus. Ops |
|
2010-04-13 |
4 |
AS |
$5.78 |
$13,005 |
D/D |
(2,250) |
47,350 |
|
- |
|
Kessler Paul D. |
SVP Clinical, Med. & Reg.; CMO |
|
2010-04-05 |
4 |
AS |
$5.30 |
$28,031 |
D/D |
(5,248) |
113,252 |
|
- |
|
Kessler Paul D. |
SVP Clinical, Med. & Reg.; CMO |
|
2010-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
36,000 |
118,500 |
|
- |
|
Fahim Raafat E F |
President, CEO and CFO |
|
2010-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
333,819 |
|
- |
|
Aryeh Jason |
Director |
|
2010-03-24 |
4 |
AS |
$6.24 |
$1,460 |
I/I |
(234) |
251,883 |
|
- |
|
Aryeh Jason |
Director |
|
2010-03-23 |
4 |
AS |
$6.25 |
$404,833 |
I/I |
(64,793) |
252,117 |
|
- |
|
Aryeh Jason |
Director |
|
2010-03-22 |
4 |
AS |
$6.24 |
$177,902 |
I/I |
(28,510) |
316,910 |
|
- |
|
Aryeh Jason |
Director |
|
2010-03-19 |
4 |
S |
$5.99 |
$46,722 |
I/I |
(7,800) |
345,420 |
|
- |
|
Aryeh Jason |
Director |
|
2010-03-18 |
4 |
S |
$5.96 |
$39,225 |
I/I |
(6,581) |
352,620 |
|
- |
|
Aryeh Jason |
Director |
|
2010-03-17 |
4 |
S |
$5.94 |
$67,881 |
I/I |
(11,419) |
359,201 |
|
- |
|
Kalnik Matthew W. |
SVP Strategic Plan. & Bus. Ops |
|
2010-03-17 |
4 |
S |
$5.93 |
$58,547 |
D/D |
(9,873) |
29,650 |
|
- |
|
Aryeh Jason |
Director |
|
2010-03-15 |
4 |
S |
$5.93 |
$1,186 |
I/I |
(200) |
370,620 |
|
- |
|
Aryeh Jason |
Director |
|
2010-03-12 |
4 |
S |
$5.93 |
$98,374 |
I/I |
(16,600) |
370,820 |
|
- |
|
Kalnik Matthew W. |
SVP Strategic Plan. & Bus. Ops |
|
2010-03-11 |
4 |
AS |
$5.95 |
$6,694 |
D/D |
(1,125) |
39,523 |
|
- |
|
415 Records found
|
|
Page 10 of 17 |
|
|